All News

Dupilumab is the first agent approved to treat EoE in this vulnerable pediatric population.

Which medications are most effective for acute migraine management? A recent study assessed which ones appeared to work best based on reported patient experience.

Among more than 1.5 million persons hospitalized for COVID-19, a history of Crohn disease or ulcerative colitis significantly increased risk for poor outcomes.

Your daily dose of the clinical news you may have missed.

Survey findings presented at the Crohn’s & Colitis Congress suggest a need for education among some health care specialists about the clinical presentation of ulcerative colitis.

The effect of vagus nerve stimulation persons with narcolepsy revealed a specific, notable improvement in daytime sleepiness in a novel open-label study.

"A meaningful percentage" of individuals with Crohn disease are treated during maintenance with biologic doses ≥20%higher than recommended in FDA labeling.

Reports of migraine-related stigma were common in a recent population-based study, with nearly one-third reporting the experience often/very often.

Gabapentinoid use increased from 4.0% of the population reporting use of the medication in 2015 to 4.7% in 2021, according to new data.

Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.

A 10-second check of your GI IQ.

Targeting "impermissible" barriers created to no-cost contraception required by the ACA, the HHS guidance follows the Biden-Harris June 2023 Executive Order on the issue.

Findings showed a high incidence of outpatient Clostridioides difficile infection despite a low rate of testing.

When does management of Crohn disease warrant assessment of C-reactive protein and fecal calprotectin and when is endoscopy indicated? Test your IBD IQ.

Your daily dose of the clinical news you may have missed.

The Boxed Warning reflects FDA research into severe adverse events including hospitalization and death in persons with CKD treated with denosumab.

Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.

The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.